ArticleNature communications2022

A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.

Tira J Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.